Grupo Chileno de Estudio de Linfoma

Cuenta oficial del Grupo Chileno de Estudio de Linfoma (GCEL)

[Dr. Chokri Ben Lamine @abouabdrahman0]

Epcoritamab + GemOx shows impressive efficacy in transplant-ineligible R/R DLBCL patients per EPCORE NHL-2 Arm 5 trial
🧬💉🩸
•ORR: 85% (CR: 61%)
•1 prior line: ORR 90%, CR 74%
•≥2 lines: ORR 83%, CR 53%
•Median DOCR: 23.6 months
•12-month OS with 1 prior line: 69%
📈⏳🧪

Safety
•Common AEs: cytopenias & CRS
•CRS mostly low-grade, all resolved
⚠️🧠✅

Conclusion:
Deep, durable responses support epcoritamab + GemOx as a promising option in R/R DLBCL ineligible for ASCT
📌🔬🛡️

🔗 Brody et al. Blood 2024; DOI: 10.1182/blood.20240206830

#HemeTwitter #DLBCL #Epcoritamab #CARBTherapy #Lymphoma #BloodCancer #ASCT #Immunotherapy #EPCORE #Hematology #PharmTwitter #OncoTwitter

[Grupo Chileno de Estudio de Linfoma @GLinfoma]

Congreso de hematopatologia !!!!!

[Rosalinda Peñaloza @rositadeolivop1]

Les compartimos la información del próximo Congreso Latinoamericano de Hematopatologia. Será un gusto poder saludarnos en Guatemala ! Y compartir y actualizarnos.🔬

[Jonathan Friedberg @DrJFriedberg]

CLL12 study supports using the watch-and-wait approach as the standard of care for early-stage CLL, including high-risk patients. Ongoin @SWOG S1925 trial evaluates early venetoclax-based treatment for high risk patients. @JCO_ASCO @DebbieMStephens https://t.co/3JgtkGjwlt

[ASH @ASH_hematology]

A bright spot 🎇in a meeting full of light was seeing all the connections made at #ASH24.

Who did you meet at the meeting? Tag them below!

[GELTAMO @geltamo]

Sequencing of therapy for patients with diffuse large B-cell lymphoma in the era of novel drugs - British Journal of Haematology | Wiley Online Library
https://t.co/OUTUfFY3FA

[Blood Journals Portfolio @BloodPortfolio]

Current and upcoming treatment approaches to common subtypes of PTCL (PTCL, NOS; ALCL; and TFHs)
https://t.co/sVR3YvsiGV #lymphoidneoplasia

[Lymphoma Hub @lymphomahub]

CONGRESS | #SOHO2024
Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL.
Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose modifications and were consistent with individual known safety profiles.
#lymsm

[Lymphoma Hub @lymphomahub]

Results of the phase III SYMPATICO trial presented at #ASCO24 show that ibrutinib + venetoclax is effective for the treatment of pts with MCL & TP35 mutations, with high CR rates & durable remissions 📝
More news: https://t.co/w5gdqqEJhi
#lymphoma #MedNews #MedEd @michaelwangmd

[Grupo Chileno de Estudio de Linfoma @GLinfoma]

A medir y suplementar!! Especialmente acá en Chile , donde el déficit de vitamina d es endémico.

[GRUPO ESPAÑOL DE LEUCEMIA LINFOCITICA CRONICA @gellc]

Vitamin D supplement for patients with early-stage chronic lymphocytic leukemia is associated with a longer time to first treatment
https://t.co/INx17iediO

[Kieron Dunleavy @DunleavyKieron]

Lymphoma Classifications, How to Develop a Future Unified Taxonomy | Journal of Clinical Oncology https://t.co/ET5VsgrQdn

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Diffuse large B-cell lymphoma at risk of secondary CNS involvement: The inefficacy of IV HD-methotrexate CNS prophylaxis & the importance of baseline cerebrospinal fluid analysis [May 10, 2023] Bennett et al. @AjHematology https://t.co/i25YCeHqXI #lymsm #btsm #CNSprophylaxis

[The Heart @ZHeart11768530]

🔴Atrial Fibrillation and Cirrhosis: Which Anticoagulant?

🔹Apixaban might present less bleeding risk than rivaroxaban or warfarin.

🔹Apixaban is associated with a roughly 3-percentage-point lower incidence of bleeding events annually

✔️https://t.co/aQY1FDHnc3

[Miguel Ángel Amor @Miguelamorg]

🖍️Infografías sobre monitorización y ajuste posológico en antifúngicos:

👉Rol de la monitorización en triazólicos
👉Recomendaciones para cada formulación
👉T de muestreo
👉Nivls valle recomendados
👉Ajustes de D en itra, posa, vori e isavuconazol

From:
https://t.co/PhlVD5RPSa

[GELTAMO @geltamo]

Testing for t(3;8) in MYC/BCL6-rearranged large B-cell lymphoma identifies a high-risk subgroup with inferior survival https://t.co/cO3nIgJmmo

[Bilal Abid, MD, MS @BilalAbidMD]

🚨"Risk of infections with bispecific antibodies in B-cell non-Hodgkin lymphomas and multiple myeloma—The current state.”
The review summarizes @US_FDA Approved BsAb. Work led by PGY1 IM, @AmritGonugunta
@BrJHaem @MDAndersonNews #BiTE #CART #infections

https://t.co/sWQK3tXaCJ

[Chan Cheah @chanyooncheah]

Good news for follicular lymphoma patients: #epcoritamab receives positive conditional marketing approval from CHMP/EMA based on phase II NHL-1 study results. Another CD20 x CD3 bispecific antibody available
https://t.co/QYIN5WQI8P
#lymSM

[Ana Lisa Basquiera @basquiera]

Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma https://t.co/CDvMofb1EZ

[Macarena Roa @hemato_maca]

Prepárate para una experiencia de aprendizaje, networking y buena onda en la 2da jornada del GCEL!
26 y 27 de Julio 2024
Double tree by Hilton , av. Kennedy 4422, Vitacura
Únete a nosotros y forma parte del cambio en el tratamiento de los linfomas. ¡No faltes!

[GELTAMO @geltamo]

Molecular diagnosis of primary CNS lymphoma in 2024 using MYD88Leu265Pro and IL-10 - The Lancet Haematology https://t.co/OrDIMjWAhS

[Grupo Chileno de Estudio de Linfoma @GLinfoma]

Fecha: [26 y 27 de Julio]
Horario: [8:30 am ]
Lugar: [Hotel DoubleTree by Hilton. Av. Kennedy Lateral 4422, Vitacura]

¡Inscríbete ya y asegura tu cupo en este importante evento del mundo de la hematología y la oncología! #GCEL #Linfoma #Networking #Hematología

[Grupo Chileno de Estudio de Linfoma @GLinfoma]

¡No te pierdas la segunda jornada del Grupo Chileno de Estudio del Linfoma (GCEL)!

Te invitamos a participar de esta imperdible cita que reunirá a algunos de los profesionales más destacados en el estudio y tratamiento del linfoma en Chile y en Latinoamérica.